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ARTICLE
Kinetic analysis of multistep USP7 mechanism
shows critical role for target protein in activity
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Farid El Oualid3, Willem J. van Dijk1, Duco van Dalen2,6, Huib Ovaa2,5, Hugo van Ingen4,7 & Titia K. Sixma1
USP7 is a highly abundant deubiquitinating enzyme (DUB), involved in cellular processes
including DNA damage response and apoptosis. USP7 has an unusual catalytic mechanism,
where the low intrinsic activity of the catalytic domain (CD) increases when the C-terminal
Ubl domains (Ubl45) fold onto the CD, allowing binding of the activating C-terminal tail near
the catalytic site. Here we delineate how the target protein promotes the activation of USP7.
Using NMR analysis and biochemistry we describe the order of activation steps, showing that
ubiquitin binding is an instrumental step in USP7 activation. Using chemically synthesised
p53-peptides we also demonstrate how the correct ubiquitinated substrate increases cata-
lytic activity. We then used transient reaction kinetic modelling to deﬁne how the USP7
multistep mechanism is driven by target recognition. Our data show how this pleiotropic DUB
can gain speciﬁcity for its cellular targets.
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Ubiquitination is an important post-translational mod-iﬁcation (PTM) that inﬂuences protein fate in every cel-lular process1,2. This modiﬁcation conjugates the C-
terminus of ubiquitin (Ub) to a lysine residue on a target protein
via an E1-E2-E3 cascade3. As Ub has 7 lysines and an available
amino terminus it can be ubiquitinated itself, resulting in poly-
ubiquitination through 8 different possible linkages4. These dif-
ferent ubiquitin marks generate distinct signals that determine the
fate of the target protein, ranging from proteasomal degradation
to cellular relocalisation or recruitment of complex partners2,5,6.
Similarly to other PTMs, ubiquitination can be
reversed, modulating and ﬁne-tuning the ubiquitin signal7.
Deubiquitination is carried out by deubiquitinating enzymes
(DUBs) that hydrolyse the isopeptide bond between Ub
and the target protein8. The activity of DUBs is tightly controlled9
and their dysfunction can lead to serious diseases, such as
cancer10,11.
One of the most abundant DUBs is ubiquitin speciﬁc protease
7 (USP7, also known as HAUSP12). It has been implicated in
several cellular processes ranging from DNA repair and apoptosis
to suppression of regulatory T-cell function13,14. Mutations in
USP7 have been shown to correlate with paediatric cancer15,16
and the protein is actively targeted for cancer therapy17–19, pri-
marily for its nuclear functions, while USP7 haploinsufﬁciency
leads to a neurodevelopmental disorder20 through a cytosolic
role.
USP7 is found in a variety of protein complexes, many of
which contain an E3 ligase and its target21. In these complexes
both the E3 ligase and its substrate are targets of USP7, like the
substrate pair of E3 ligase MDM2 and target p5322, the master
regulator of the response to cellular stress23. This creates a
situation where USP7 can either deubiquitinate and stabilise
MDM2, promoting p53 ubiquitination and its proteasomal
degradation24,25, or target p53, preventing degradation and acti-
vating the apoptotic pathway26. The choice between these two
targets is inﬂuenced by various other proteins shifting USP7
activity towards MDM227 or p5328.
For the interaction with both MDM2 and p53, USP7 relies on
its N-terminal TRAF (Fig. 1a) domain on USP7. This domain
interacts with a TRAF recognition motif on the target proteins
with a moderate afﬁnity of ~10 µM29,30, but does not affect the
actual hydrolysis of the ubiquitin isopeptide bond on a minimal
substrate31. The TRAF domain is connected to the adjacent cat-
alytic domain (CD) through a ﬂexible linker30, allowing the CD to
ﬁnd and cleave off the ubiquitin from the target (Fig. 1a). This
catalytic domain alone has low intrinsic deubiquitinating activity
while full-length USP7 is a much more active DUB32. Crystal
structures of this CD show that the apo state of the enzyme has an
inactive conformation, with a misaligned catalytic triad33. When
ubiquitin is bound, the catalytic triad (C223, H464 and D481)
realigns into an active conformation, which involves signiﬁcant
changes in a loop above the active site. This ‘switching loop’ is
essential for full activity of full-length USP731.
Located C-terminally of the CD are ﬁve ubiquitin-like (Ubl)
domains which are essential for the increased activity of full-
length USP731,32. The three Ubl domains just downstream of the
CD (Fig. 1a) do not inﬂuence the activity directly, but rather serve
as a binding platform for interactors such as GMPS or
DNMT131,34,35. The last two Ubl domains with the activating tail
(Ubl45), however, are indispensable for full activity of USP7:
Ubl45 readily activates the CD as does the very C-terminal tail by
itself, at high concentrations36.
The Ubl domain region can adopt an extended conformation,
as seen in the crystal structure of Ubl12345 (PDB: 2YLM), but has
considerable ﬂexibility, as shown by small-angle X-ray scattering
(SAXS)31. Detailed biochemistry combined with SAXS analysis
led to a proposed mechanism where the Ubl domains curve and
the Ubl45 domain ‘folds back’ onto the CD. The C-terminal tail
then interacts with the ‘switching loop’, stabilising a catalytically
competent conformation of USP7. Various mutations in either
the tail or the loop substantiated this model31. The role of the C-
terminal tail was further deﬁned in a crystal structure of
ubiquitin-bound CD linked to Ubl45. This showed how the C-
terminal tail binds the CD, stabilising the ‘switching loop’36 in the
active conformation. Intriguingly, fusion of just the C-terminal
peptide to CD can reconstitute much of the activation, but from
the structure it was unclear whether it was bound in cis or trans.
This ambiguity prompted us to further investigate the role of the
Ubl45 domain in this interaction and its effect on USP7 activity.
Most molecular studies on DUB activity utilise minimal sub-
strates, focussing on the role of the ubiquitin moiety, essentially
the product of the reaction. In the last years the focus has
therefore shifted towards Ub-chains4, uncovering chain-
speciﬁcity of DUBs, which allowed relating them to distinct
biological processes37. For USP7 the active conformation of the
catalytic domain has only been observed in the ubiquitin-
conjugated complex33. Ubiquitin alone is not sufﬁcient to induce
the rearrangement and a fusion at its C-terminus (such as ubi-
quitin aldehyde or a ubiquitinated substrate) is required for
proper active site rearrangement38.
The roles of target proteins, however have received relatively
little attention in biochemical DUB analyses. Quantifying con-
tributions of a realistic substrate requires a homogeneous, well-
deﬁned target. For p53, the interaction with USP7 has been
described in detail29,39, allowing generation of synthetic mimics
of the substrate. Using such ubiquitinated p53 mimics as model
targets, we investigate the effect of this more realistic substrate on
USP7 activity in an in vitro setting.
With these chemical tools we address how a p53 model sub-
strate interaction may modulate the activation process. Structural
analysis suggests that monomeric USP7 undergoes an activation
process that can be further improved by binding to a valid sub-
strate. Using the p53 model substrate and global modelling of the
experimental data, we could determine the order of events and
quantify the steps involved in the USP7 ubiquitin hydrolysis
cycle.
Results
USP7 activation requires the C-terminal tail in cis. The acti-
vation of USP7 requires interaction between the CD and the C-
terminal peptide (see Fig. 1a for domain deﬁnitions and
nomenclature). The details of this interaction were described in a
recent crystal structure (PDB: 5JTV) of Ubl45 and CD36. This
structure clariﬁes how the activating C-terminal peptide binds,
but the connection to Ubl45 was disordered, making it difﬁcult to
establish whether the C-terminus of USP7 binds into the acti-
vation cleft in cis or in trans.
When we analysed the ability of USP7 to form dimers in size-
exclusion chromatography with multi-angle laser light scattering
detection (SEC-MALLS), we observed no dimerization for full-
length (FL) USP7 (injected at 20 µM, peak elutes at ~4 µM) and
only partially for the construct used in the crystallization
experiment (injected at 45 µM, monomer peak elutes at ~7 µM)
(Fig. 1b). This suggests that at the much lower concentration
found in cells (~0.3 µM40), USP7 is more likely to exist as a
monomer.
We then checked what concentrations of Ubl45 are needed for
in trans activation of CD (Fig. 1c). We ﬁnd that in trans
activation is possible, but only occurs at high concentrations, with
an apparent KD of 110 µM (Fig. 1d). Consistently, a construct
lacking the C-terminal tail (CD12345ΔC) can be activated by a
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catalytically dead FL USP7, (CD12345C223A) only at high
concentrations, with an apparent KD of 60 µM (Fig. 1e). Both
these apparent in trans activation constants are orders of
magnitude higher than the concentrations (1–20 nM) that are
sufﬁcient for USP7 activity assays of full-length or CD-Ubl45
constructs31. We therefore conclude that, although trans
activation of USP7 is possible at high concentrations, it cannot
be the predominant mechanism of its self-activation.
Deﬁnition of the interaction interface between CD and Ubl45.
If USP7 acts as a monomer, this means that the interaction of CD
and Ubl45 occurs in cis. The interaction of the C-terminal peptide
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Fig. 1 USP7 activation by the C-terminal tail happens in cis. a Schematic domain representation of USP7 and constructs used in this study. Active site
residues and domain names are indicated: TRAF TRAF domain, CD Catalytic domain, 1–5 Ubl domains 1 through 5, tail. The activating C-terminal peptide
(res. 1083–1102), marked in purple. The graphical representation of the constructs is used in other ﬁgures. b Analysis of USP7 constructs on SEC-MALLS
shows monomer/dimer equilibrium. CD45 (100 µL of 45 µM) or FL (80 µL of 20 µM) were loaded on a Superdex 200 gel ﬁltration column. Absorbance at
280 nm (dark red: CD45; dark blue: FL) was monitored and eluted peaks were analysed for molecular weight (red: CD45; blue: FL) by in-line MALLS. For
CD45 the molecular weights of the monomer (69 kDa) and dimer (138 kDa) are indicated with the dotted line. c Activation of USP7CD by Ubl45 requires
the very C-terminal tail. CD (20 nM) was mixed with Ubl45 variants as indicated and tested for DUB activity using UbRho. d USP7CD (20 nM) was
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this dimerization-dependent activation of USP7 happens at micromolar concentrations in line with afﬁnity of 1d. Binding of ubiquitin substrate to
CD12345C223A causes an inhibitory effect above 2 µM, therefore only lower concentrations were used to extrapolate a KD,app (blue dashes). The red dotted
lines indicate the activity of WT CD12345 for comparison
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with CD, as determined by Rougé et al. in the crystal structure36,
is indisputable, but the positioning of the Ubl45 core did not seem
as well-deﬁned. We therefore wanted to investigate this interac-
tion in solution. We used NMR spectroscopy to map the binding
interface between CD and Ubl45 (Fig. 2, Supplementary meth-
ods). First we assigned the backbone resonances of Ubl45 (Sup-
plementary Figure 1a) and performed prediction of secondary
structure in solution. Since this matched the crystal structure
(PDB: 5JTV, Supplementary Figure 1b), we concluded that the
NMR conditions allow functional interaction analysis.
We then analysed the interaction of Ubl45 with CD. We
titrated the unlabelled CD (42 kDa) into isotope-labelled Ubl45
(25 kDa) up to a ratio of 1:10 and followed changes in peak
position or intensity (Fig. 2a, b). Upon addition of CD, we
observe only very minor chemical shift perturbations (CSPs)
(Fig. 2b), but a marked decrease in intensity for residues in the
core of the Ubl45 domains (Fig. 2c). The size of the decrease
agrees well with the formation of a 67 kDa complex with afﬁnity
as determined by SPR (see below and Supplementary Figure 2a).
Under these conditions, residues with large changes in their
chemical environment upon binding are expected to show an
even more dramatic intensity loss (Supplementary Figure 2b-c).
From the absence of such effect for residues that are predicted to
be in the interface based on the crystal structure (Fig. 2d) or for
any other site on the core surface, we conclude that the Ubl45
core is not involved in a single, speciﬁc interaction with CD. Only
a few, very minimal CSPs are observed, localized to C-terminal
tail residues, with the strongest shift seen for Y1093 (Fig. 2b). The
tail residues however remain sharp and intense peaks throughout
the titration, indicating that the tail is not immobilized on the CD
surface.
This is surprising, since the tail is immobilised in the crystal
structure, but this was solved in the presence of ubiquitin.
Therefore, we wondered if ubiquitin could promote the binding
of the tail. We generated a covalent complex with ubiquitin, as
ubiquitin monomers bind poorly to USP7CD38, We used a
suicide probe, ubiquitin-propargyl (Ub-PA41) to generate CDUb
(Supplementary Figure 3a). In an NMR titration of CDUb into
labelled Ubl45, we observed interaction only through a decrease
in peak intensity, which was nearly directly proportional to the
equivalents of CDUb added. At 30% of CDUb added, peak
intensity for all Ubl45 residues, including the C-terminal residues,
was reduced by ~30% (Fig. 2e). This indicates that Ubl45 forms a
tight complex with CDUb. Now also the tail, and particularly the
C-terminal residues are immobilized. Meanwhile we do not
observe signiﬁcant CSPs. This absence indicates that the free
protein is in slow exchange with the complex (75 kDa) (see also
Supplementary Figure 2b-c).
Together, these results suggest that while the Ubl45 binds to
CD, it does so in multiple, weak binding modes predominantly
involving the Ubl45 core to form a dynamic complex. Our data
further suggest that the presence of ubiquitin or a ubiquitinated
target can induce the speciﬁc binding mode of the C-terminal tail
as observed in the crystal structure.
Interaction between Ubl45 and CD does not require the tail.
For full activity the C-terminal tail is essential, but its afﬁnity for
the catalytic domain could only be measured indirectly. In surface
plasmon resonance (SPR) experiments, interaction was not
detectable31, but in an activation assay, the apparent KD-value
was estimated at ~1000 µM36. This is one order of magnitude
weaker than the apparent KD determined for Ubl45 (110 µM,
Fig. 1d). Our NMR results also suggested that the Ubl domains
contribute to the binding and activation of the catalytic domain.
To investigate the interaction between Ubl45ΔC and the catalytic
domain we immobilised GST-USP7CD on the SPR chip, ﬂowing
over the tailless construct Ubl45ΔC. We were able to detect
binding at high concentrations. Extrapolation of the curve, sug-
gests a KD of 420 µM (Fig. 3a), similar to that observed for the C-
terminal peptide interaction in the activity assay. This suggests
that both Ubl45ΔC and the tail bind weakly to the CD.
We then tested the afﬁnity of CD for Ubl45 including the tail,
and get an approximate KD of 280 µM (Fig. 3a), comparable to
the tailless construct. This suggests that the C-terminal tail is not
the main driving force for the interaction between the CD and
Ubl45 as the afﬁnity is similar with or without the tail. This result
is in agreement with the lack of binding between the C-terminal
peptide and CD observed in the NMR experiment (Fig. 2c) and
earlier data31, but seems at odds with the activating role of the tail
in the activity assay. The NMR experiment seemed to suggest that
ubiquitin needs to be present for immobilization of the tail on
CD.
Interaction between C-terminal tail and CD requires Ub. To
quantify the effect of ubiquitin on the binding of the activating C-
terminal tail, we again used ubiquitin covalently coupled to the
catalytic cysteine of the CD (CDUb). As CD on its own has low
activity, the reaction between Ub-PA and CD had to be driven to
completion using the trans activation of Ubl45. After incubation
however, Ubl45 could not be separated from CDUb on gel ﬁl-
tration (Supplementary Figure 3a) requiring additional ion
exchange chromatography. This indicates that complex formation
between CDUb and Ubl45 is tighter than predicted, as a complex
with a KD of 280 µM (Fig. 3a) generally dissociates during this
type of gel ﬁltration experiment.
We quantiﬁed the interaction by SPR ﬂowing CDUb over GST-
immobilised Ubl45 (Fig. 3b). Data analysis in EvilFit42 identiﬁed
a KD of 0.59 μM with a standard deviation of ±0.03 and a koff of
0.8 s−1 (Supplementary Figure 3b) for the interaction between
CDUb and Ubl45. The presence of ubiquitin in CD therefore
increased the afﬁnity 400-fold compared to CD only (Fig. 3c). As
the C-terminal tail is necessary for activation, we hypothesised
that it would directly facilitate the interaction with the
intermediate, ubiquitin-bound, state. To test this, we immobilised
the tailless construct (Ubl45ΔC) in our SPR experiment setup and
ﬂowed over CDUb with concentrations up to 80 µM (Fig. 3b). We
could not detect any binding of Ubl45ΔC in this experiment,
suggesting that the Ubl domains can no longer bind ubiquitin-
bound catalytic domain, contrary to apo CD (Fig. 3a). This would
mean that, after ubiquitin binding, the increased activity depends
exclusively on the C-terminal tail.
In agreement to this, the immobilised tail peptide (residues
1083–1102) interacted with CDUb with a KD of 2.6 µM, but
showed no binding to the CD alone (Fig. 3d and Supplementary
Figure 3c). This is analogous to what we found for Ubl45 (Fig. 3b)
and in line with our NMR experiments where the tail did not
show clear binding to CD alone (Fig. 2c) but was immobilized by
CDUb.
Our results are in line with previously published NMR data
that showed that a linked Ub is necessary to induce rearrange-
ment of the catalytic site38. The binding of ubiquitin to CD
apparently facilitates binding of the C-terminal tail (Fig. 3d).
Together, these data explain how CD can still be activated by the
C-terminal tail on its own, albeit with a lower resulting activity
than the FL construct36. We conclude that once the ubiquitin-
bound intermediate state is achieved, the C-terminal tail is
sufﬁcient for self-activation.
Ubl45ΔC promotes ubiquitin binding. Knowing that the C-
terminal tail has high afﬁnity for CD only after ubiquitin binding
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(Fig. 3e), we wondered if Ubl45ΔC might affect the Ub binding.
Such an outcome is consistent with our previous results indi-
cating that in full-length USP7 self-activation increases the cat-
alytic rate (kcat) but also the KM (which is, on a minimal substrate,
dominated by the afﬁnity to ubiquitin), from >>35 µM to roughly
4 µM31. It may also explain why direct linkage of the C-terminal
peptide to the CD almost, but not completely recapitulates the
full-length activity36.
We therefore tested ubiquitin binding qualitatively in a
ﬂuorescence polarization (FP) assay, following polarisation of
TAMRA-labelled Ub upon incubation with various USP7
constructs (Fig. 3f). In this assay, we see the increased afﬁnity
for ubiquitin in the presence of the Ubl45 domain (when
comparing CD12345 with CD only) even when the tail is absent
(comparing CD12345ΔC to CD). The data indicate that the
presence of the C-terminal tail does not affect the CD afﬁnity for
Ub, in line with its lack of afﬁnity for CD observed in the NMR
(Fig. 2b) and SPR experiments (Fig. 3d).
We could conﬁrm the Ubl45-induced increase in afﬁnity of CD
for Ub by analysis of the steady-state kinetics of these constructs
in activity assays (Fig. 3g). When we ﬁt Michaelis-Menten curves
for CD, CD12345 and CD12345ΔC we could see that presence of
a
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the C-terminal tail dramatically increases kcat31; whereas, the
Ubl45ΔC is responsible for the increase in KM (compare CD and
CD12345ΔC in Fig. 3g).
A multi-step mechanism for USP7 activity. These data suggest
that USP7 is likely to follow a multi-step mechanism during its
catalytic cycle. In the ﬁrst step, binding of ubiquitin is facilitated
by the core of Ubl45, which does not involve the C-terminal tail.
After binding of ubiquitin, conformational changes align the
catalytic triad33. In this state, the afﬁnity of the CD for Ubl45 is
decreased (Fig. 3e), but the afﬁnity for the tail is dramatically
increased, allowing optimal orientation of the activating C-
terminal tail to form the activated state. This mechanism is
reminiscent of the classical-induced ﬁt in enzymology, where
binding of the substrate can activate the enzyme: here, ubiquitin-
induced binding of the C-terminal peptide stabilizes the active
CD conformation and promotes fast hydrolysis of substrate,
which is observed as an increase in kcat.
Next, we wanted to address the role of the target protein in the
USP7 mechanism. To study whether interactions with a
ubiquitinated target protein would affect USP7 activation we
make use of a chemical biology approach.
Role of the target p53. We chose p53 as our model target protein
(Fig. 4a), which has six lysines near the C-terminus that can be
ubiquitinated39 as well as motifs that can be recognized by the
USP7 TRAF domain29,43. We made a synthetic toolbox of ubi-
quitinated C-terminal p53 peptides44 and initial tests on these
conjugates indicated that all six lysines could be cleaved by USP7.
We generated two versions of the ubiquitinated p53 peptides
with K382 as the ubiquitination site, either with the TRAF
recognition motif (p53Ub, res. 357–389) or without this region
(p53shortUb, res. 368–389, Fig. 4a). The ubiquitin attachment was
varied to allow different assays: a suicide version with a
vinylamide (VA) linkage (I)45 that can bind covalently, like the
better-known vinyl methyl ester46,47, a non-hydrolysable triazole
linkage (II)48 and a cleavable native isopeptide linkage (III)44,49,
for both the short and long versions of the peptide (Fig. 4b).
Using the p53UbVA suicide probes, we were able to assess the
role of the TRAF interaction in substrate binding. Although both
short and long versions of the probe reacted readily with
CD12345 (Fig. 4c, Supplementary Figure 4), the full-length USP7,
which contains the TRAF domain, showed increased complex
formation, speciﬁcally for the p53Ub peptide that has the TRAF
recognition sequence. This indicates that the TRAF recognition
sequence promotes the USP7 interaction with the model
substrate. In the remainder of this report we will focus on the
long peptide.
Next, we used the p53UbVA probe to generate a non-
hydrolysable complex with TCD, a construct that lacks all Ubl
domains (Fig. 1a) to address whether the p53 interaction affects
the interaction of CD with Ubl45. Using SPR, the complex was
ﬂowed over immobilised Ubl45 and we could determine the
afﬁnity between Ubl45 and TCD-p53Ub (Fig. 4d, Supplementary
Figure 3d). With a KD of 2.9 µM it is similar to the afﬁnity found
for the C-terminal tail interacting with CDUb (2.6 µM, Fig. 3d).
Apparently the presence of the TRAF-p53 interaction does not
further change the interaction with Ubl45. This is in line with the
fact that the presence of the TRAF domain does not affect activity
on a minimal substrate31 or the association of the activating
Ubl45 domain.
A second p53 interaction. To further investigate the role of the
p53 peptide interaction with the TRAF domain in the activation
process, we decided to look at the afﬁnity between USP7 and the
model target. As previous reports have alluded to an additional
binding site (other than TRAF) for the USP7 targets p53 and
MDM2 in the C-terminal domains of USP750, we ﬁrst assessed
the binding of the peptide to USP7 constructs in a FP assay
(Fig. 5a). These direct binding assays with TAMRAp53 peptide
conﬁrmed the presence of an additional p53 binding site and map
it to the Ubl45 domains, without requiring the C-terminal tail
(compare FLΔC and TCD45 to TCD). Interestingly, this addi-
tional interaction site depends on the TRAF domain since
CD12345 alone does not bind the peptide at these concentrations
(Fig. 5a). These results suggest an extended binding interface
between the TRAF-CD and the p53 peptide that is aided by
Ubl45, but the hypothesis of a second, very weak, binding site
within Ubl45 cannot be excluded.
To then assess a potential increase in afﬁnity for the
ubiquitinated substrate, we used the non-hydrolysable compound
(Fig. 4b; p53Ubinh) as inhibitor in an activity assay, on minimal
substrate UbRho (Fig. 5b). We found that both the TRAF domain
(compare TCD and CD) as well as Ubl12345 improve the IC50
independently (Fig. 5c). However, the full-length construct
displays a further avidity effect, resulting in an IC50 of 16 nM,
~60-fold better than either TCD or CD12345. This underlines
that the TRAF domain, CD and Ubl12345 all contribute to the
effective substrate (p53Ub) recognition and that the sum of these
interactions yields a tight, effective interaction.
Visualisation of the multi-step enzymatic mechanism. As both
the ubiquitin acceptance (aided by Ubl45) and the target
Fig. 3 Afﬁnity of CD for Ubl45 increases with Ub present and is dependent on C-terminal tail. a SPR binding results indicate a weak afﬁnity of USP7CD for
either Ubl45 or Ubl45ΔC. CD was immobilized through GST on the chip and tested for binding with Ubl45 or Ubl45ΔC. Equilibrium binding values were
plotted against concentration and ﬁtted to get an estimated KD. Responses were normalised using Bmax and standard deviation for resulting values is given.
b The increased binding between Ubl45 and CDUb depends on the C-terminal tail. Ubl45 or Ubl45ΔC was immobilized on the chip and the covalent CDUb
complex was ﬂown over. A ﬁt was made using the equilibrium binding values yielding a KD of 590 nM for Ubl45, whereas no binding could be observed for
Ubl45ΔC. Normalisation was carried out using Bmax. c Comparison of the afﬁnity of Ubl45 for CD or CDUb shows a remarkable increase. Curves from A and
B are replotted to exemplify the change in KD. d The C-terminal tail was immobilized using biotin and CD or CDUb was ﬂown over to conﬁrm that the tail
interacts with the transition state (CDUb) only and not the apo CD. e Overview of afﬁnities between Ubl45 and CD show that Ub enhances the binding of
the tail. The values for the upper two rows are determined using SPR, see a–d. The values in the last row have been derived from activity assays, see Fig. 1d
and36 for the estimated afﬁnity of the C-terminal tail (*). N.A. not applicable; N.D. No binding detected. f The presence of the Ubl45 domain is essential for
increased afﬁnity of CD for ubiquitin, but not the C-terminal tail. The afﬁnity for ubiquitin was measured in an FP assay where TAMRA-labelled ubiquitin
was incubated with various USP7 constructs. g Steady-state kinetics analysis of USP7 constructs indicates that the C-terminal tail mainly affects the
catalytic rate, while the presence of Ubl45 without the tail enhances the afﬁnity for the ubiquitin substrate. The Michaelis-Menten constant (KM) and kcat
were obtained by ﬁtting the initial velocity data for various concentrations of UbRho. For a–e, obtained values are displayed ± SD after ﬁtting. For f–g data
points are the mean ± SD of n= 2 measurements
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recognition positively inﬂuence deubiquitination, we wanted to
explore how these collaborate during the deubiquitination process
and whether there is a deﬁned order of events. To this end, we
utilised the synthetic ubiquitinated p53 target with a native
linkage (Fig. 4b; p53Ub) and a ﬂuorophore at the N-terminus of
the p53 peptide to allow tracking of substrate and product44. We
monitored the substrate during its hydrolysis in an FP assay
where 100 nM of TAMRA-labelled reagent is incubated with
various USP7 constructs (Fig. 6b for FL, Supplementary Figure 5-
7b for TCD, CD12345 and CD). Both FL and CD12345 could
readily hydrolyse the substrate, resulting in a drop of the FP
signal. The other two constructs, CD and TCD, required higher
concentrations in order to see a decrease in FP signal, while the
TCD construct actually started out with an increased signal
(Supplementary Figure 5b). This increased signal would be a
result of binding, as the TRAF domain increases the afﬁnity for
the p53-substrate, but the rate of catalysis is still low for TCD.
Although these experiments efﬁciently monitored substrate
hydrolysis, we were interested in the early events that could not
be caught in our plate reader setup.
To get insight into the very early phase of the reaction, we
decided to use a stopped-ﬂow setup (Fig. 6c, d). We followed the
reaction by ﬂuorescence polarization, which is sensitive to the size
of the complex (as this affects the tumbling rate and thus
polarisation), and by ﬂuorescence intensity, which responds to
changes in local conformation affecting the ﬂuorophore. As these
experiments were performed under near-equimolar amounts of
enzyme and substrate, we also measured binding to the product
TAMRAp53 peptide in this stopped-ﬂow setup (Fig. 6e, f).
In the stopped-ﬂow anisotropy data, we could detect an
increase in signal when we titrated FL into TAMRAp53Ub (Fig. 6c).
After this binding phase (0.02–0.2 s) we observe a decrease in
anisotropy, indicating a second phase (0.2–2 s) indicative of
hydrolysis. The signal however does not drop below baseline for
the highest concentration, indicating retention of the product, in
line with our p53 peptide binding data (Fig. 6e).
For the constructs CD and CD12345 we can hardly detect the
TAMRAp53Ub binding phase (Supplementary Figure 6, 7) or
the decrease in anisotropy, indicating that these require the
presence of the TRAF domain. When TRAF is present, in TCD,
both binding (increase in anisotropy) and hydrolysis (decrease in
anisotropy) are visible (Supplementary Figure 5c), but the
decrease only occurs after a lag phase (>5 s), indicating the
presence of intermediate states between binding and hydrolysis.
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This step is more explicitly visualised in the intensity data from
these stopped-ﬂow experiments. For TCD (Supplementary
Figure 5), with the long delay between binding and hydrolysis,
we see a signiﬁcant decrease in intensity in this delay
(Supplementary Figure 5d), which we interpret as a
conformational change in the protein (see Supplementary
methods). For full-length USP7 a minor intensity increase
(Fig. 6d) occurs, with a slight delay (0.05–0.5 s) relative to
the binding phase. This suggests that a further conformational
change affects the intensity signal, which we interpret as binding
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of the C-terminal tail, read out by rearrangement of the TAMRA
label. The non-synchronicity of the events in the anisotropy and
intensity experiments suggests that multiple steps are involved in
the hydrolysis mechanism.
Kinetic analysis of USP7 activity on p53 model substrate. To
model these multiple steps we describe every phase, with as few
reaction steps as possible. We imported the raw stopped-ﬂow, FP
and activity data into KinTek51 and scaled the data based on the
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negative controls (Supplementary methods). This rendered the
data interpretable by KinTek modelling with a minimal set of
reaction equations. To be able to model the non-synchronous
changes in the FP and intensity signals we introduced inter-
mediate steps in the reaction (Fig. 6h). These include binding
events (Steps 1, 6 and 7), conformational changes (Steps 2, 3 and
5) and the enzymatic hydrolysis (Step 4). The introduction of
these steps allowed a good ﬁt to the data and made it possible to
derive rate constants (kf and kr) for every step of the mechanism
(Fig. 6h).
For the shorter constructs, introduction of one intermediate
step between the binding (Step 1) and the hydrolysis step (Step 4,
Supplementary Figure 5, 6, 7) was sufﬁcient to ﬁt the
experimental traces. For the full-length construct however a
second intermediate step was necessary to match the model to the
experimental data.
The order of release of the reaction products p53 and Ub could
not be determined based on activity data alone. Therefore, we
used their respective afﬁnities (Fig. 3f, 5a) to set the order of
release. This order, with later release of the p53 peptide, also
allowed adding afﬁnity data for the secondary binding site to the
model, as induced by Ubl45 (Fig. 5a), which ﬁtted well in the
stopped-ﬂow data (Fig. 6e, f).
The modelling of the experimental curves allowed us to tease
apart the various steps that USP7 performs in catalysis and
reveals how the different domains affect the target processing. For
instance, the intensity decrease observed upon p53Ub binding by
the TCD construct (Supplementary Figure 5d) is not seen for FL
(Fig. 6d). We can interpret this absence as an effect of the ‘folding
back’ of the Ubl domains towards the CD31 and changing the p53
interaction50. Likewise, the long delay time, seen for TCD, is
much shorter for constructs that still contain the Ubl domains. As
these domains activate CD, it seems reasonable to assume the
delay time in TCD is required to remodel the catalytic site into an
active conformation33 without help of the Ubl domains.
The KinTek analysis results in a model where we can quantify
each component (Fig. 6g) and reaction kinetics (Fig. 6h). In the
ﬁrst step, anisotropy changes are interpreted as binding of
substrate p53Ub (Step 1; Fig. 6h). This is followed by multiple
changes in intensity which are interpreted as conformational
changes (Steps 2 and 3). Next, the intensity rises and the
anisotropy decreases (Step 4), interpreted as hydrolysis and
release of the ubiquitin product. Further intensity changes (Step
5) take place before p53 peptide release returns USP7 to the
ground state (Step 6).
Validation and evaluation of the kinetic model. Our kinetic
model fully agrees with the order of events observed in NMR and
SPR analysis in Figs. 2–3. We decided to test whether this could
be used quantitatively as an independent control. We applied the
model to ﬁt the analysis of the minimal substrate, UbRho (Fig. 6a,
Supplementary Figure 5a, 6a, 7a). Besides validating the kinetic
model, this would also allow better deﬁnition of the rate constants
by co-reﬁning the values within KinTek. The intermediate states
were used in the ﬁtting, making a direct comparison between the
ubiquitinated target protein and the minimal substrate possible.
For the FL construct the efﬁciency of the reaction precluded ﬁt-
ting the intermediate steps in the minimal substrate analysis, so
we only used steps 1, 4 and 7 (Fig. 6h).
The validity of the ﬁtted constants was then analysed using the
FitSpace module of KinTek52. Here we found that only TCD and
FL data had sufﬁcient amplitudes to allow for a full statistical
analysis (Supplementary Figure 8). To avoid overﬁtting within
this analysis, we linked rate constants (Supplementary Figure 8a,
d), testing the statistical relevance for their ratios rather than
their absolute values. The overall result indicated a well-
constrained model where Step 2, the catalytic rearrangement, is
the rate-limiting step. Finally, we converted the rate constants
into steady-state kinetics parameters using the appropriate
formula for one (Supplementary Figure 8f) or two (Supplemen-
tary Figure 8c) intermediates53 (Supplementary Figure 5g, 6f,
Fig. 6h). This yielded KM and kcat values for all steps. The
values for the minimal substrate are similar to those
determined previously31, validating the descriptions used in our
modelling.
USP7 activity is driven by target recognition. The conversion to
steady-state parameters allows for easy comparison of USP7
activity on minimal substrate and the p53 model substrate. The
combined increased activity (kcat/KM) is ~11,000-fold, for FL on
p53Ub relative to CD on UbRho. Interestingly, on the p53Ub
substrate kcat is slightly diminished as soon as a TRAF domain is
present, but this is offset by the improved target recognition (here
expressed as KM) leading to substantially increased processivity.
These ﬁndings indicate that, although studies on a minimal
substrate are essential in studying the enzymatic mechanism,
using a realistic substrate can give better understanding of the
working of a DUB and its possible regulation.
Discussion
Here we studied USP7 self-activation by its C-terminal peptide
and its target protein. We show that although trans activation by
self-association is possible at high concentrations, the normal
USP7 self-activation happens in cis. We show that interaction of
Ubl45 with the CD promotes ubiquitin binding and only this
promotes the correct positioning of the C-terminal peptide next
Fig. 6 A quantitative kinetic model for USP7 enzymatic activity through global ﬁtting. Icons in each panel indicate the substrate used. The lines describe the
ﬁt of the data in the various experiments performed: a Minimal substrate activity assay of USP7FL (1 nM), using a dilution range of UbRho. b FP enzyme
activity assay on TAMRAp53Ub (100 nM). The amounts of USP7 are indicated. After conversion to p53Ub amounts (lower panel) a delay time (DT) was
introduced. c Stopped ﬂow FP enzyme activity assay on TAMRAp53Ub (50 nM), the anisotropy signal allows observation of the early binding and hydrolysis
phases. Areas marked in grey were not included in the ﬁt as they represent the mixing time (<0.001 s) or a timescale where bleaching effects start to
dominate (>10 s). d Intensity readings of the experiment in c indicates a change in chemical environment upon binding of substrate. e Like c for using
peptide only (25 nM p53) shows equivalent binding phases as the full substrate. f Intensity readings of the experiment in e. All stopped-ﬂow experiment
are an addition of n= 10 separate measurements. g Behaviour of p53-substrate states during overall model in an equimolar (1–1; 50 nM) ratio of enzyme
and substrate. Intermediate states as in h. hModel used for KinTek ﬁtting with kinetic constants obtained. USP7FL indicated as USP7, intermediates with #
or *. For binding steps (Step 1, 6 and 7) on-rates are in µM−1 s−1 and off-rates in s−1. Rates for conformational changes (Step 2, 3 and 5) are in s−1. The
forward reaction for enzymatic hydrolysis (Step 4) is in s−1, but the reverse step (labelled with θ) was assumed irreversible (ﬁxed at 0 µM−1 s−1). Equation
constants with matching Greek characters (α, β, γ and δ) were linked in the reﬁnement. The on-rate for binding steps (labelled with ε) is diffusion-
controlled, determined separately and ﬁxed during modelling. These on- and off-rates reﬂect the optimal ratio that models the individual steps with their
respective SD (±), as the experiment does not have sufﬁcient resolution to fully resolve rates. For both UbRho and p53Ub the resulting steady-state
parameters were calculated to allow for a direct comparison (last column)
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to the catalytic site. Thus self-activation takes place in multiple
distinct steps. Next we showed how the substrate protein
strengthens activation and provided a kinetic model for the
cooperative activation process.
The combination of our ﬁndings allows us to generate an
updated model for the USP7 mode of action (Fig. 7). Ubiquiti-
nated targets associate initially with the TRAF domain (Step 1,
Fig. 7) and this binding is improved by the additional p53 binding
+
Ub
Ub
Ub
Ub
p53
Ub
p53
Ub
Ub
p53
Ub
TR
AF
1
23
4
5
TR
AF
1
234
5
1. p53Ub binds USP7
2. Catalytic triad rearranges
3. Tail binds to stabilise active state
4. Hydrolysis of Ub-bond and release
5. Release of tail
6. p53 release
USP7 activity mechanism
′OPEN′ STATE ′CLOSED′ STATE
USP7 + p53Ub USP7.p53Ub
USP7.p53Ub USP7*.p53Ub
USP7*.p53Ub USP7#.p53Ub
USP7#.p53Ub USP7*.p53 + Ub
USP7 + p53 USP7.p53
USP7*.p53 USP7.p53
DESCRIPTION
MODEL EQUATION
USP7FL
Fig. 7 Kinetic model for USP7 mechanism on p53Ub The kinetic model (equations) and their interpretation are depicted schematically. The weak afﬁnity
between Ubl45 and CD suggests that free USP7 is in equilibrium between an ‘open’ and ‘closed’ state31. The p53Ub substrate is bound by TRAF and CD, as
well as an additional binding site that depends on the Ubl domains (1). Ubiquitin binding induces a rearrangement of the catalytic triad33 (2), which
dramatically increases the afﬁnity the activating C-terminal tail, but diminishes the contact between CD and Ubl45. Binding of the tail peptide (3) stabilises
the active state. This promotes the hydrolysis of the isopeptide bond, allowing Ub release (4). This in turn diminishes afﬁnity for the C-terminal tail, causing
its release (5) and the subsequent release of the p53 peptide (6) to return USP7 to the ground state
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site, induced by presence of the Ubl domains (Fig. 5c). The target
association brings the attached ubiquitin in close proximity to the
catalytic domain, overcoming its poor afﬁnity for ubiquitin,
enhanced by the Ubl45 domain (Fig. 3f). The binding of ubiquitin
into the active site (Step 2) not only induces rearrangements of
the catalytic triad33, but also reduces intramolecular interaction
with Ubl45 (Fig. 3e) and promotes binding of the activating C-
terminal tail, through a dramatic increase in afﬁnity (Fig. 3)
where it stabilises the active conformation (Step 3). In this acti-
vated state the hydrolysis of the isopeptide bond (Step 4) occurs
much faster than for CD only31.
After hydrolysis, release of products takes place, which we
modelled according to their respective afﬁnities. In full-length
USP7 the leaving ubiquitin has a poor afﬁnity compared to the
p53 peptide (Fig. 5c), so we expect Ub to leave ﬁrst (Step 4),
leaving p53 bound to USP7, enabling a change due to the addi-
tional binding site (Step 5). The p53 release (Step 6) is modelled
here as the last step in order to let USP7 return to the ground
state, but given the tight interaction (160 nM) and the protein
concentrations found in cells the p53-USP7 complex may last
longer in vivo. Another ubiquitinated substrate or additional
regulatory step could be required to perturb this complex and
release p53.
With this model we assumed a sequential order of reactions
(Supplementary methods) and we could not model all steps
explicitly (Supplementary Figure 7). Nevertheless, the modelled
intermediate steps agree very well with our SPR experiments that
were not used for the model (Fig. 3). Based on the model we can
separate intermediates in both time and place, allowing to con-
nect species tested by SPR to states found in the kinetic model.
Thus we see that Ubl45ΔC is responsible for the increased KM
whereas the C-terminal tail for the faster kcat31.
It is clear from our data that USP7 activation follows a mul-
tistep activation scheme that generates high speciﬁcity for the
target. As USP7 interacts with many different targets21, such a
mechanism could make sure activity is targeted to the right
substrate at the right time. Our results indicate that the substrate
recognition collaborates with the intrinsic self-activation.
The complexity of the self-activation provides regulatory
opportunities through external factors. One example is hyper-
activation by GMPS31, but other binding partners, such as ICP0
and DNMT135,54 and/or post-translational modiﬁcations may
further affect activity.
Interestingly, the p53 peptide collaborates with the C-terminal
domains through the additional binding site that we quantiﬁed.
An earlier report suggested binding in the Ubl domains to both
p5350 and MDM236, but whether such a bipartite binding of
substrates by USP7 is a common theme in other substrates
remains to be investigated. Further deﬁnition of the different
interactions would be needed to explain why USP7 usually prefers
MDM2 over p5325,55.
Our data provide opportunities for speciﬁc targeting in drug
discovery programmes: both the secondary substrate binding site
and the self-activation by Ubl45 are allosteric sites of interest.
Working out the speciﬁcs of the interaction, using our NMR
backbone assignment for Ubl45 and the recent assignment of
CD56, can be helpful in this process. Better molecular under-
standing of this interaction would help to design inhibitors spe-
ciﬁcally targeted at USP7 self-activation.
In this study, we employed both a model substrate and the
minimal substrate to assess the USP7 mechanism of action. The
usefulness of the ubiquitinated model substrate is not only illu-
strated by our ﬁndings on the activity effect of the TRAF domain,
it also allowed us to monitor intermediate steps of the reaction
and the order in which they occur. Combining these chemical
ubiquitin tools with a domain-by-domain approach we could
pinpoint what part of USP7 is important in which part of the
hydrolysis cycle. The results highlight the importance of
the target protein and hopefully these insights will allow for the
development of more speciﬁc USP7 inhibitors, targeting USP7
activity on speciﬁc substrates.
Methods
Constructs and mutations. USP7 constructs (Fig. 1a) were based on the codon-
optimized sequence (Addgene, #63573)31. USP7-TCD was cloned into pGEXNKI-
GST-3C using ligase-independent cloning57. Constructs lacking the C-terminal tail
were made by introducing a stop codon at residue 1083 using site-directed
mutagenesis. Mutation constructs were introduced using partially overlapping
primers and Phusion Flash polymerase (Thermo Fisher). All clones were sequence-
veriﬁed and agreed with the published sequence12.
Protein expression. USP7 constructs that included the TRAF region were
expressed in Escherichia coli BL21 Rosetta2 (DE3) using Terriﬁc Broth medium
and overnight induction using 0.2 mM IPTG at 18 °C. Other USP7 constructs were
expressed in E. coli BL21 cells using overnight auto-induction in LB at 18 °C58.
Isotope-labelled USP7-Ubl45 intended for interaction analysis by NMR was
expressed in E. coli BL21 cells using M9 minimal medium supplemented with
15NH4Cl (CortecNet), glucose, vitamin mix and micronutrient mix59. For three-
dimensional NMR experiments 13C-glucose (CortecNet) was used. To acquire
deuterated sample, D2O (CortecNet) was used to make the medium. Cells were
grown in 5 mL LB from a single colony and transferred to a 50 mL minimal
medium preculture after washing to grow overnight at 37 °C. The preculture was
dispensed in 4 L minimal medium and cells were grown until OD600 reached 0.6.
Protein expression was then induced overnight at 18 °C by addition of 0.2 mM
IPTG.
Protein puriﬁcation. Expressed proteins were isolated from the lysate using
Glutathione Sepharose 4B beads (GE Healthcare) in GST buffer (50 mM HEPES,
pH 7.5, 250 mM NaCl, 1 mM EDTA, 1 mM DTT). After elution, using GST buffer
with 15 mM GSH added, the GST tag was removed using 3C protease under
dialysis against PorosXQ buffer A (20 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM
DTT). The sample was subsequently applied to PorosXQ anion exchange (Thermo
Fisher) and eluted using a gradient of buffer B (20 mM HEPES, pH 7.5, 1 M NaCl,
1 mM DTT). After analysis appropriate fractions were pooled, concentrated and
further puriﬁed on a Superdex gel ﬁltration column (GE Healthcare) using GF
buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT). The peak fractions
were pooled, concentrated up to 10 mgmL−1 and ﬂash frozen34.
MALLS experiments. Puriﬁed protein was run on a Superdex 200 gel ﬁltration
column (GE Healthcare) using GF buffer (20 mM HEPES, pH 7.5, 100 mM NaCl,
1 mM DTT) in line with a MiniDawn Tristar (Wyatt Technologies) Multi-Angle
Laser Light Scattering (MALLS) detector, connected to a Shodex RI 101 (SHOWA
DENKO K.K.) refractive index detector. Wyatt Technologies software (ASTRA)
was used to determine the corresponding peaks’ molecular weight based on the
refractive index.
Deubiquitination assays on a minimal substrate. Enzyme activity of USP7 was
measured using the ﬂuorescence of rhodamine upon cleavage of the quenched
minimal substrate UbRho (Ubiquitin-Rhodamine110Gly, Ub-Rh110Gly; UbiQ, the
Netherlands). Experiments were performed in running buffer (20 mM HEPES, pH
7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA and 0.05% v/v Tween-20). Protein
samples were prepared at 2X concentration and added to 8 µM UbRho just before
measuring, reaching an end volume of 20 µL in the plate. The release of rhodamine
was measured at the emission wavelength of 520 nm (±10 nm) after excitation at
485 nm (±10 nm) in a Pherastar plate reader (BMG LABTECH GmbH, Germany).
Either the raw data were plotted directly in Prism 7 (GraphPad), or the slopes were
converted to initial velocity values for plotting against the titration range. Assays
were performed three times with two different protein batches.
For steady-state kinetics analysis a single concentration of USP7 constructs
(CD, CD12345 and CD12345ΔC) was incubated with a dilution range of UbRho
and assessed for activity using the same experimental setup as described above. The
initial velocities were determined using the linear slope of the reaction and plotted
against the concentration UbRho used. Using Prism 7 the data were ﬁtted using the
Michaelis-Menten equation, yielding the reported steady-state kinetics parameters.
For kinetics analysis in KinTek, a concentration series of UbRho was used with
USP7 constructs FL, (1 nM), TCD and CD (both 20 nM). To get resolution at the
earliest time points the assay was performed using the injector, injecting the
enzyme into the UbRho solution followed by direct detection (as described above).
The resulting values were converted to rhodamine concentrations before being
loaded into KinTek.
NMR experiments. All NMR experiments were carried out on Bruker Avance III
HD spectrometer operating at 850MHz 1H Larmor frequency and equipped with a
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cryoprobe. All NMR spectra were processed using Bruker TopSpin or NMRPipe60.
NMR samples for assignment contained 180 µM USP7-Ubl45 with either uniform
1H, 15N, 13C or fractional 2H, uniform 15N, 13C labelling in 50 mM HEPES, pH 7.5,
100 mM NaCl, 7% D2O and 1mM DTT (NMR buffer). Backbone resonances of
Ubl45 were assigned to 84% completeness, using 3D TROSY HNCO, HN(CA)CO,
HNCA, HNCOCA, HNCB, HNCOCB, HNCACB, and CBCA(CO)NH spectra.
Assignment was done using CCPN61. The program TALOS62 was used to analyse
the secondary structure based on the assigned backbone chemical shifts.
Titration of 1H15N-labelled Ubl45 (45 µM) with either USP7CD (using Ubl45:
CD molar ratios of 1:0, 1:1, 1:5 and 1:10) or USP7CDUb (using ratios of 1:0.1 and
1:0.3) were performed after extensive dialysis of the proteins to NMR buffer. We
monitored residue-speciﬁc intensity change and chemical shift perturbations (CSP)
of Ubl45 amide backbone resonances in 2D 1H15N TROSY spectra. The CSPs were
calculated from the perturbations in the 1H (ΔδH) and 15N (ΔδN) dimensions as
the weighted average (composite) CSP in ppm according to ref. 63. The intensity
changes were plotted against residue number for the end point of both titrations.
Synthesis of p53-conjugated ubiquitin reagents. Both ubiquitin and the C-
terminus of p53 were produced synthetically by solid phase peptide synthesis, for
the native reagent the p53 peptide was N-terminally labelled with 5-
carboxytetramethylrhodamine (TAMRA). The peptide was linked to ubiquitin
using click chemistry or native chemical ligation49 to yield the non-hydrolysable48,
natively linked44 and covalently binding45 p53Ub and p53shortUb probes. Details
are available in Supplemental methods section.
Generation of covalent ubiquitin-USP7 complexes. A total of 120 µM CD was
incubated overnight with an excess of Ub-PA64 and Ubl45 (both 150 µM) under
dialysis (against 20 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT), yielding 80%
of the CD reacted with the ubiquitin probe. The sample was subjected to anion
exchange (PorosXQ) and gel ﬁltration (Superdex 75) to remove unreacted ubi-
quitin and Ubl45. Fractions were concentrated for use in afﬁnity assays. For USP7-
TCD a similar approach was used, only substituting p53UbVA for Ub-PA, resulting
in 100% reaction.
Surface plasmon resonance assays. All surface plasmon resonance (SPR)
experiments were carried out on a Biacore T200 machine (GE Healthcare) at 25 °C.
A polyclonal GST antibody from the GST capture Kit (GE Healthcare) was
covalently bound on a CM5 sensor chip via amino coupling. Two-hundred units of
GST-tagged USP7 constructs were immobilised on the test ﬂow cell, whilst the
blank ﬂow cell had an equal amount of GST only immobilised. The C-terminal
peptide (residues 1083–1102) was synthesized with a biotin at the N-terminus and
immobilized up to ~30 RU on a SA chip. A concentration series of USP7 constructs
with or without covalently bound ubiquitin probe was tested for binding using
running buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA
and 0.05% v/v Tween-20) supplemented with 1 mgmL−1 BSA and 1mgmL−1
dextran.
Interaction values (KD) were determined by plotting steady-state equilibrium
values against the concentration and ﬁtting these with 1:1 stoichiometry using
Prism 7 (Graphpad). For easy comparison purpose, responses were normalised
using Bmax. For binding curves with detectable dissociation and a KD below 10 µM
we used EvilFit42 to determine kinetic rate constants. All experiments were
performed at least in duplo and representative curves are shown.
Fluorescence polarization binding assays. To measure the afﬁnity for ubiquitin,
N-terminally tetramethylrhodamine (TAMRA) labelled ubiquitin was incubated
with a titration range of each USP7 construct. All assays were performed in run-
ning buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA and
0.05% v/v Tween-20) on a Pherastar plate reader (BMG LABTECH GmbH, Ger-
many), using excitation wavelength 540 nm (±20 nm) and detection of polarization
at 590 nm (±20 nm). The anisotropy of TAMRAUb was calibrated at 35 mA, any
change in anisotropy upon USP7 interaction was calculated using MARS data
analysis software (BMG LABTECH GmbH, Germany) and plotted using Prism 7
(GraphPad).
The afﬁnity between the USP7 constructs and a TAMRA-labelled p53 peptide
(TAMRAp53) was measured on a ClarioStar plate reader (BMG LABTECH GmbH,
Germany). Assays were performed in triplo using the same running buffer and
wavelength ﬁlters (Ex. 540 ± 20 nm, Em. 590 ± 20 nm). TAMRAp53 anisotropy was
calibrated to be 35 mA and changes in anisotropy were plotted and ﬁtted in Prism
7 to obtain afﬁnities.
The p53 FP binding assay was repeated for USP7FL using a stopped-ﬂow setup.
25 nM of TAMRAp53 was incubated with a concentration range of USP7 in running
buffer. The binding was monitored using an excitation wavelength of 548 nm on a
TgK Scientiﬁc instrument (model SF-61DX2) equipped with photomultiplier tube
R10699 (Hamamatsu) and Kinetic Studio was used to merge ten separate,
sequential injections for each protein concentration.
USP7 inhibition assays. USP7 constructs were incubated for 30 min in assay
buffer (50 mM Tris-HCl, pH 7.6, 100 mM NaCl, 2 mM cysteine, 1 mg mL−1
CHAPS) with various concentrations of the non-hydrolysable p53Ubinh construct,
prior to assessment in a deubiquitination assay. To account for difference in
activity, protein concentrations were adapted for FL (0.35 nM), CD12345 (0.35
nM), TCD (200 nM) and CD (75 nM), whilst the substrate (UbRho) concentration
was kept constant at 0.4 µM. Protein samples and substrate were prepared at 4× the
ﬁnal concentration. The initial raw velocities were derived and plotted against the
titration range of inhibitor reagent. Using Prism 7 the data were ﬁtted to yield IC50-
values.
Fluorescence polarization activity assays. Various USP7 constructs at indicated
concentrations were incubated with 100 nM of TAMRA-labelled, natively linked
p53Ub (TAMRAp53Ub) to trace the binding and hydrolysis of the reagent. Assays
were performed in assay buffer (20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 1 mM
DTT and 1 mgmL−1 CHAPS) on a Pherastar plate reader measuring at 590 nm
after excitation at 540 nm. The FP signal for TAMRAp53Ub only was used as a
starting baseline, whilst the TAMRA-labelled p53-peptide represents the fully
cleaved reagent.
The ﬂuorescence polarization activity assays were repeated in a stopped-ﬂow
setup. USP7 constructs at three concentrations (50 nM, 25 nM and 12.5 nM) were
incubated with 50 nM of TAMRAp53Ub to trace the binding and hydrolysis of the
reagent. TAMRAp53Ub was monitored in running buffer (20 mM HEPES, pH 7.5,
150 mM NaCl, 1 mM DTT and 0.05% v/v Tween-20) using an excitation
wavelength of 548 nm on a TgK Scientiﬁc instrument (model SF-61DX2) equipped
with photomultiplier tube R10699 (Hamamatsu), the manufacturer’s software
(Kinetic Studio) was used to merge the ten measurements performed for each
concentration.
KinTek modelling. All data used were imported into KinTek with concentrations
in µM and time in seconds: for minimal substrate activity curves, converted to
released rhodamine, could be loaded into KinTek directly. The curves resulting
from USP7 inhibition assays were read with a delay time of 120 s. The FP activity
assay data from the stopped-ﬂow instrument could also be read-in directly. With
the data for every construct imported, the model (Fig. 6h) was ﬁtted per construct
separately for each experiment. When the ﬁts proved stable, reaction constants
were linked and a global ﬁt was performed. The resulting values were then sta-
tistically tested using the FitSpace module of the Kintek software. For detailed
information see Supplementary Methods.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
NMR assignments for Ubl45 (residues 890–1102) are deposited in the Biomole-
cular Magnetic Resonance Bank (BMRB 27627). Other datasets generated during
and/or analysed during the current study are available from the corresponding
author on reasonable request. The source data underlying Figs. 1–6 and Supple-
mentary Figures 1–7 are provided as a Source Data ﬁle. A reporting summary for
this article is available as a Supplementary Information ﬁle.
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